Ponezumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePonezumab
Drug Alias Nameponezumabum泊奈珠单抗珀奈珠单抗RI-1219PF-04360365 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer DiseaseCerebral Amyloid Angiopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseCerebral Amyloid Angiopathy

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG